210 related articles for article (PubMed ID: 24836441)
1. Erlotinib: early clinical development in brain cancer.
Addeo R; Zappavigna S; Parlato C; Caraglia M
Expert Opin Investig Drugs; 2014 Jul; 23(7):1027-37. PubMed ID: 24836441
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
Halatsch ME; Schmidt U; Behnke-Mursch J; Unterberg A; Wirtz CR
Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082
[TBL] [Abstract][Full Text] [Related]
3. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Raizer JJ
J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma.
Gao Q; Lei T; Ye F
Expert Opin Investig Drugs; 2013 Aug; 22(8):1023-40. PubMed ID: 23731170
[TBL] [Abstract][Full Text] [Related]
5. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
Lassman AB; Rossi MR; Raizer JJ; Abrey LE; Lieberman FS; Grefe CN; Lamborn K; Pao W; Shih AH; Kuhn JG; Wilson R; Nowak NJ; Cowell JK; DeAngelis LM; Wen P; Gilbert MR; Chang S; Yung WA; Prados M; Holland EC
Clin Cancer Res; 2005 Nov; 11(21):7841-50. PubMed ID: 16278407
[TBL] [Abstract][Full Text] [Related]
6. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
Mellinghoff IK; Wang MY; Vivanco I; Haas-Kogan DA; Zhu S; Dia EQ; Lu KV; Yoshimoto K; Huang JH; Chute DJ; Riggs BL; Horvath S; Liau LM; Cavenee WK; Rao PN; Beroukhim R; Peck TC; Lee JC; Sellers WR; Stokoe D; Prados M; Cloughesy TF; Sawyers CL; Mischel PS
N Engl J Med; 2005 Nov; 353(19):2012-24. PubMed ID: 16282176
[TBL] [Abstract][Full Text] [Related]
7. Pathogenetic pathways leading to glioblastoma multiforme: association between gene expressions and resistance to erlotinib.
Löw S; Vougioukas VI; Hielscher T; Schmidt U; Unterberg A; Halatsch ME
Anticancer Res; 2008; 28(6A):3729-32. PubMed ID: 19189657
[TBL] [Abstract][Full Text] [Related]
8. Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer.
Nakata A; Gotoh N
Expert Opin Ther Targets; 2012 Aug; 16(8):771-81. PubMed ID: 22762482
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib.
Halatsch ME; Löw S; Hielscher T; Schmidt U; Unterberg A; Vougioukas VI
Anticancer Res; 2008; 28(6A):3725-8. PubMed ID: 19189656
[TBL] [Abstract][Full Text] [Related]
10. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts.
Gadji M; Crous AM; Fortin D; Krcek J; Torchia M; Mai S; Drouin R; Klonisch T
Eur J Pharmacol; 2009 Dec; 625(1-3):23-30. PubMed ID: 19836372
[TBL] [Abstract][Full Text] [Related]
11. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.
Minniti G; Muni R; Lanzetta G; Marchetti P; Enrici RM
Anticancer Res; 2009 Dec; 29(12):5171-84. PubMed ID: 20044633
[TBL] [Abstract][Full Text] [Related]
13. A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor.
Iyer R; Bharthuar A
Expert Opin Pharmacother; 2010 Feb; 11(2):311-20. PubMed ID: 20088749
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
Zhang J; Yu J; Sun X; Meng X
Cancer Lett; 2014 Aug; 351(1):6-12. PubMed ID: 24861428
[TBL] [Abstract][Full Text] [Related]
16. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
17. Overview of tyrosine kinase inhibitors in clinical breast cancer.
Agrawal A; Gutteridge E; Gee JM; Nicholson RI; Robertson JF
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S135-44. PubMed ID: 16113090
[TBL] [Abstract][Full Text] [Related]
18. The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment.
Guo G; Narayan RN; Horton L; Patel TR; Habib AA
Curr Cancer Drug Targets; 2017; 17(3):297-302. PubMed ID: 28004613
[TBL] [Abstract][Full Text] [Related]
19. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F
J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392
[TBL] [Abstract][Full Text] [Related]
20. EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells.
Struve N; Riedel M; Schulte A; Rieckmann T; Grob TJ; Gal A; Rothkamm K; Lamszus K; Petersen C; Dikomey E; Kriegs M
Oncotarget; 2015 Oct; 6(32):33867-77. PubMed ID: 26418954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]